Ets-1 and hypoxia inducible factor-1α inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer

Prostate

Volumn 70, Issue 2, 2010, Pages 162-169

  Kosaka, Takeo ^a   Miyajima, Akira ^a   Shirotake, Suguru ^a   Kikuchi, Eiji ^a   Hasegawa, Masanori ^a   Mikami, Shuji ^a   Oya, Mototsugu ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenesis; Angiotensin II; Angiotensin II type 1 receptor; Ets 1; Hormone refractory prostate cancer; Hypoxia inducible factor 1 ; Renin angiotensin system; VEGF

Indexed keywords

ANDROGEN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; CANDESARTAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; TRANSCRIPTION FACTOR ELK 1; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR BLOCKING; UPREGULATION; WESTERN BLOTTING;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEIN C-ETS-1; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM;

EID: 73449142487     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21049     Document Type: Article

References (33)

1. Catalona WJ. Management of cancer of the prostate. N Engl J Med 1994;331(15):996-1004.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96.
3. Helin K, Stoll M, Meffert S, Stroth U, Unger T. The role of angiotensin receptors in cardiovascular diseases. Ann Med 1997; 29(1):23-29.
4. Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis 2008;29(9):1675-1684.
5. Chow L, Rezmann L, Catt KJ, Louis WJ, Frauman AG, Nahmias C, Louis SN. Role of the renin-angiotensin system in prostate cancer. Mol Cell Endocrinol 2009;302(2):219-229.
6. Khakoo AY, Sidman RL, Pasqualini R, Arap W. Does the reninangiotensin system participate in regulation of human vasculogenesis and angiogenesis? Cancer Res 2008;68(22):9112-9115.
7. Page EL, Robitaille GA, Pouyssegur J, Richard DE. Induction of hypoxia-inducible factor-1alpha by transcriptional and translational mechanisms. J Biol Chem 2002;277(50):48403-48409.
8. Richard DE, Berra E, Pouyssegur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J Biol Chem 2000;275(35):26765-26771.
9. Kosaka T, Miyajima A, Takayama E, Kikuchi E, Nakashima J, Ohigashi T, Asano T, Sakamoto M, Okita H, Murai M, Hayakawa M. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate 2007;67(1):41-49.
10. Kosugi M, Miyajima A, Kikuchi E, Horiguchi Y, Murai M. Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin Cancer Res 2006;12(9):2888-2893.
11. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86(3): 353-364.
12. Miyajima A, Kosaka T, Asano T, Seta K, Kawai T, Hayakawa M. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 2002;62(15):4176-4179.
13. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3(10):721-732.
14. Zhan Y, Brown C, Maynard E, Anshelevich A, Ni W, Ho IC, Oettgen P. Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling. J Clin Invest 2005;115(9): 2508-2516.
15. Wasylyk B, Hahn SL, Giovane A. The Ets family of transcription factors. Eur J Biochem 1993;211(1-2):7-18.
16. Mikami S, Oya M, Mizuno R, Murai M, Mukai M, Okada Y. Expression of Ets-1 in human clear cell renal cell carcinomas: implications for angiogenesis. Cancer Sci 2006;97(9):875-882.
17. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994;57(3):406-412.
18. Ghosh PM, Malik SN, Bedolla RG, Wang Y, Mikhailova M, Prihoda TJ, Troyer DA, Kreisberg JI. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation. Endocr Relat Cancer 2005;12(1):119-134.
19. Chua CC, Hamdy RC, Chua BH. Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta 1998;1401(2):187-194.
20. Oettgen P. Regulation of vascular inflammation and remodeling by ETS factors. Circ Res 2006;99(11):1159-1166.
21. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 1997; 157(6):2329-2333.
22. Silberman MA, Partin AW, Veltri RW, Epstein JI. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 1997;79(4):772-779.
23. Dittmer J. The biology of the Ets1 proto-oncogene. Mol Cancer 2003;2:29.
24. Pearse DD, Tian RX, Nigro J, Iorgulescu JB, Puzis L, Jaimes EA. Angiotensin II increases the expression of the transcription factor ETS-1 in mesangial cells. Am J Physiol Renal Physiol 2008; 294(5):F1094-F1100.
25. Nakayama T, Ito M, Ohtsuru A, Naito S, Nakashima M, Fagin JA, Yamashita S, Sekine I. Expression of the Ets-1 proto-oncogene in human gastric carcinoma: correlation with tumor invasion. Am J Pathol 1996;149(6):1931-1939.
26. Yordy JS, Muise-Helmericks RC. Signal transduction and the Ets family of transcription factors. Oncogene 2000;19(55):6503-6513.
27. Takai N, Miyazaki T, Fujisawa K, Nasu K, Miyakawa I. Expression of c-Ets1 is associated with malignant potential in endometrial carcinoma. Cancer 2000;89(10):2059-2067.
28. Fujimoto J, Aoki I, Toyoki H, Khatun S, Tamaya T. Clinical implications of expression of ETS-1 related to angiogenesis in uterine endometrial cancers. Ann Oncol 2002;13(10):1605-1611.
29. Khatun S, Fujimoto J, Toyoki H, Tamaya T. Clinical implications of expression of ETS-1 in relation to angiogenesis in ovarian cancers. Cancer Sci 2003;94(9):769-773.
30. Kosugi M, Miyajima A, Kikuchi E, Kosaka T, Horiguchi Y, Murai M, Oya M. Angiotensin II type 1 receptor antagonist enhances cis-dichlorodiammineplatinum- induced cytotoxicity in mouse xenograft model of bladder cancer. Urology 2009;73(3):655-660.
31. Nickenig G, Roling J, Strehlow K, Schnabel P, Bohm M. Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms. Circulation 1998;98(22): 2453-2460.
32. Xu ZG, Yuan H, Lanting L, Li SL, Wang M, Shanmugam N, Kato M, Adler SG, Reddy MA, Natarajan R. Products of 12/15-lipoxygenase upregulate the angiotensin II receptor. J Am Soc Nephrol 2008;19(3):559-569.
33. Thekkumkara TJ, Thomas WG, Motel TJ, Baker KM. Functional role for the angiotensin II receptor (AT1A) 3′-untranslated region in determining cellular responses to agonist: Evidence for recognition by RNA binding proteins. Biochem J 1998;329(Pt 2): 255-264.